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Microvesicles (MVs) are emerging as a novel means to enact cell-to-cell 
communication in inflammation. Here, we aimed to ascertain the ability of 
neutrophil-derived MVs to modulate target cell behaviour, the focus being 
the macrophage.  
MVs were generated in response to tumour necrosis factor-α, from healthy 
control neutrophils or those from rheumatoid arthritis patients. MVs were 
used to stimulate human monocyte-derived macrophages in vitro, or 
administered intra-articularly in the K/BxN mouse model of arthritis. A 
macrophage/fibroblast-like synoviocyte co-culture system was used to 
study the effects of vesicles on the crosstalk between these cells. 
We demonstrate a direct role for phosphatidylserine and annexin-A1 
exposed by the MVs to counteract classical activation of the macrophages, 
and promote the release of transforming growth factor-β, respectively. 
Classically-activated macrophages exposed to neutrophil MVs no longer 
activated fibroblast-like synoviocytes in subsequent co-culture settings. 
Finally, intra-articular administration of neutrophil MVs from rheumatoid 
arthritis patients in arthritic mice affected the phenotype of joint 
macrophages. 
Altogether these data, with the identification of specific MV determinants, 
open new opportunities to modulate on-going inflammation in the synovia 
– mainly by affecting macrophage polarisation and potentially also 
fibroblast-like synoviocytes - through the delivery of autologous or 
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Highlights 
 Neutrophil microvesicles restrict the inflammatory activation of 
macrophages by presenting phosphatidylserine to Mer 
 Annexin A1 expressed on neutrophil microvesicles induces 
macrophage release of TGFβ by activating FPR2 
 Neutrophil microvesicles restrict the ability of macrophages to 
activate fibroblast-like synoviocytes 
 
Research in context 
All cells release small, spherical parcels of information, called vesicles, 
that they use to send signals between each other. One immune cell type, 
the neutrophil, has been shown to release vesicles which prevents other 
immune cells from becoming hyperactive: herein we focus on rheumatoid 
arthritis. This paper demonstrates that vesicles released from neutrophils 
are able to prevent another immune cell type, the macrophage, from 
becoming activated. The importance of this is that this mechanism is 
occurring naturally, and if we can understand it, we may be able to use 
















Released directly from the plasma membrane of virtually all cells in 
response to calcium signalling, microvesicles (MV; also termed 
microparticles or more generically extracellular vesicles) are right-side 
out, double membrane-enclosed structures with a 100-1000nm diameter. 
The varied composition of MV, which contain lipids, proteins and nucleic 
acids, and downstream efficacy depend upon their cellular source and 
activation stimulus (van der Pol et al., 2012). Present in a variety of 
biological fluids, MVs can impart both homeostatic and pathophysiological 
functions on local and distant tissues.  
 
Despite their propensity to drive acute inflammation, neutrophils are one 
of few populations of cells whose MVs are known to promote tissue 
protection, and in some cases repair, by affecting function and phenotype 
of target cells (Dalli et al., 2008; Eken et al., 2008; Gasser & Schifferli, 
2004). Of these, macrophages are central to the recovery of homeostasis 
after an inflammatory insult, and controlling their phenotype is desirable 
in chronic inflammatory diseases, including rheumatoid arthritis (RA). 
Macrophages are remarkably plastic in their ability to change phenotype 
and respond to a wide spectrum of stimuli. In response to the Th1 
cytokine interferon gamma (IFN-γ) and toll-like receptor ligands such as 
lipopolysaccharide (LPS), macrophages upregulate expression of major 
histocompatibility complex type II (MHCII), the co-stimulatory molecule 














Biswas & Mantovani, 2010). In RA, these pro-inflammatory macrophages 
drive disease progression and cartilage erosion by i) recruiting other 
immune cells (Misharin et al., 2014; Vogelpoel et al., 2014), ii) promoting 
fibroblast-like synoviocyte (FLS) activation (Wilkinson et al., 1993), and 
iii) undergoing osteoclastogenesis (Fujikawa et al., 1996). 
 
At the polar end of the macrophage phenotype spectrum, macrophages 
stimulated with Th2 cytokines such as IL-4, express scavenger receptors 
like CD206 and the anti-inflammatory cytokines IL-10 and transforming 
growth factor-β (TGF-β) (Gordon, 2003). These pro-resolution/wound 
healing macrophages reduce leukocyte recruitment (Dean et al., 2008; 
Bellac et al., 2014), exhibit efferocytic capacity to remove apoptotic 
neutrophils (Zizzo et al., 2012; McCauley et al., 2014) and promote tissue 
remodelling and repair (Huynh et al., 2002; Rigamonti et al., 2014; Harel-
Adar et al., 2011). While these distinct, polar phenotypes are readily 
generated in vitro, whether macrophages in complex tissues separate into 
discrete populations seems to depend on the tissue/disease context 
(Martinez & Gordon, 2014). Of note, macrophage heterogeneity in the 
arthritic synovium has not yet been fully characterised (Ma & Pope, 2005), 
nonetheless, attenuating or even reversing a pro-inflammatory 
polarisation in synovial macrophages may favour resolution and repair 















We have previously demonstrated that neutrophil-derived MVs promote 
chondrocyte survival and proteoglycan deposition by stimulating TGF-β 
production (Headland et al., 2015). Such an effect was partly reliant on 
the pro-resolution protein annexin A1 (anxA1; Perretti et al., 2017). There 
is some evidence that neutrophil MVs can modulate macrophage 
responses (Martin et al., 2012; Dalli & Serhan, 2012), however how these 
effects are attained is only partly understood. At the same time, the 
downstream consequences of macrophage exposure to neutrophil-derived 
MVs have not been investigated.  
 
Here we studied the properties of neutrophil MVs on human monocyte-
derived macrophages identifying at least some of the effectors responsible 
for changes in cell polarization. oreover, we investigate how such 
changes would impact downstream on macrophage/FLS crosstalk. Of 
potential therapeutic relevance, the most salient effects were replicated by 
MVs prepared from RA patient circulating neutrophils. 
 
MATERIALS AND METHODS 
Patients  
All volunteers gave written, informed consent to blood collection and the 
procedure was approved by the East London & The City Local Research 
Ethics Committee references 05/Q0603/34 and 07/Q0605/29 for healthy 
controls and for arthritis patients, respectively. Whole blood was drawn 














anticoagulated by mixing with sodium citrate (0.32% w/v). All blood cells 
are from healthy controls unless indicated otherwise in figure legends. 
Patient data for arthritis patients are shown in Supplementary Table S1. 
 
Isolation of neutrophils and mononuclear cells  
Whole blood was centrifuged at 130xg for 20 min and plasma was 
removed. For every 30 mL of whole blood, erythrocytes were depleted by 
sequentially layering 8mL of 6% w/v dextran (high molecular weight, 
31392-250G, Sigma-Aldrich, Poole, UK, in PBS) onto each 10mL blood. 
After 15 min, the leukocyte-rich fraction was layered over Histopaque 
1077 (10771, Sigma-Aldrich) and centrifuged for 30 min 450xg at room 
temperature to separate granulocytes from peripheral blood mononuclear 
cells (PBMC). Neutrophils were washed once by centrifuging at 300xg and 
re-suspended in phenol red-free RPMI for further use. 
 
Generation of monocyte-derived macrophages  
A 500µL aliquot of PBMC containing 0.9×106 cells was seeded in a 24-well 
suspension culture plate. After 1hr incubation at 37oC, cells were washed 
to remove lymphocytes and incubated with 50ng/mL macrophage-colony 
stimulating factor (M-CSF; 300-25, PeproTech, London, UK) in RPMI+10% 
v/v foetal bovine serum, with medium replaced on day 5.  On day 7, 
macrophages were washed twice with PBS and used as needed. 
 














Monocyte-derived macrophages were stimulated for 24hr at 37oC with 
10ng/mL LPS (E.Coli 0111:B4, L2630, Sigma-Aldrich) and 20ng/mL IFN-γ 
(300-02, PeproTech) or 50ng/mL IL-4 (200-04, PeproTech). In some 
cases, specific inhibitors and blockers were used including 10nM UNC-569 
(445835-10MG, Millipore, Billerica, USA), 10μg/mL anti-anxA1 (clone 1B; 
produced in house) or 10μg/mL isotype control (14-4714-85, eBioscience, 
San Diego, USA). Neutrophil MVs were also added at the indicated 
concentrations.  Supernatants were collected for Cytometric Bead Array 
for IL-12p70, IL-1β, IL-10 and TGF-β (558264, BD Biosciences, San Jose, 
USA) following manufacturer’s instructions. Cells were detached, blocked 
in 160μg/mL human IgG (G4386, Sigma-Aldrich) at 4oC for 15 min, and 
labelled with 1.25μg/mL anti-HLADR/DP/DQ-FITC, 1μg/mL anti-CD86-PE, and 
4μg/mL anti-CD206 antibodies at 4oC for 30 min. Cells were acquired on a 
LSRFortessa cytometer. 
 
Generation and isolation of neutrophil MVs  
Neutrophils (2×107 cell/mL) were stimulated with 50ng/mL TNF-α (T0157-
10UG, Sigma-Aldrich) for 20 min at 37oC before placing on ice. Cell 
suspensions were centrifuged at 4,400xg at 4oC for 15 min to pellet cells 
and contaminating platelets, followed by a second centrifugation at 
13,000×g at 4oC for 2 min to remove residual contaminants (e.g. 
apoptotic bodies). MVs were enriched from exosomes by centrifuging at 
20,000xg at 4oC for 30 min.  Exosomes were pelleted by centrifuging the 














supernatant was removed and the pellets were re-suspended in sterile 
PBS. 
 
Nanoparticle tracking analysis (NTA) 
MV preparations were analysed using an NS300 Nanoparticle Tracker with 
488nm scatter laser and high sensitivity camera (Malvern Instruments 
Ltd., Malvern, UK). For each sample, particle scatter was recorded 3 times 
for 60 seconds each under flow conditions (arbitrary speed 50) at camera 
level 16 and analysis threshold 5, using the NTA 3.2 acquisition and 
analysis software. 
 
ImageStream™ analysis of vesicles  
MVs were analysed and counted using fluorescence triggering on an 
ImageStreamx MKII imaging cytometer as described previously (Headland 
et al., 2014). Briefly, vesicles were labelled with 50μM boron-
dipyrromethene (BODIPY) texas red or BODIPY maleimide fluorescein (D-
6116 & B10250 respectively, Life Technologies, Carlsbad, USA) as 
appropriate, and were acquired on their own or after labelling with either 
2μg/mL anti-CD14-PE/Cy7 (400125, Biolegend San Diego, USA), 2μg/mL 
anti-CD66b-FITC (400107, Biolegend), 10μg/mL anti-anxA1 followed by 
2μg/mL anti-mouse IgG-BV241 (405317, Biolegend) (each antibody 
incubation performed at 4oC for 30 min) or with annexin A5 (anxA5) 
following manufacturer’s instructions (51-46121E, BD Biosciences). AnxA5 














free buffer; all protein antigen-positive events were gated using 
fluorescence minus one (FMO) controls. 
 
MV uptake 
MVs were labelled with 5μM CFSE before pelleting and re-suspending in 
PBS. In three different experiments, microvesicles (5x106) were incubated 
for 15 min at room temperature with either 50μg/mL annexin A5 (or 
vehicle) or 10μg/mL anti-anxA1 (clone 1B) antibody (or isotype-matched 
control), or macrophages were incubated for 15 min at 37oC with 10nM 
UNC-569 or vehicle, prior to cultures in 6-well suspension wells and 
incubated at 37oC for 5-90 min. Then, macrophages were detached and 
acquired on an ImageStreamx MKII. 
 
Macrophage-FLS co-cultures  
Monocyte-derived macrophages were obtained as above on 6-well 3μm 
pore Transwell™ inserts (353091, Scientific Laboratory Supplies, 
Nottingham, UK). Following 24hr treatment as indicated, Transwells™ 
were washed twice with PBS and placed into a 6-well plate containing 
glass coverslips with confluent FLS (408RAK-05a, Cell Applications Inc., 
San Diego, USA), such that the Transwell™ membrane was in contact with 
both fibroblasts and macrophages. After 24hr at 37oC, 1x Golgi block 
(4980-03, eBioscience) was added to the culture medium for the last 6hr 
of culture. Fibroblasts were labelled with 0.5μg/mL anti-VCAM-1-BV711 














Biolegend) antibodies at 4oC for 30 min, fixed and permeabilised with an 
Intracellular Fixation & Permeabilization kit (88-8824-00, eBioscience), 
and labelled at 4oC for an additional 30 min with 1μg/mL anti-TNF-α-
BV605 (502935, Biolegend), 1μg/mL anti-IL-6-BV421 (563279, BD 
Biosciences) and 1μg/mL anti-MCP-1-PE (505903, Biolegend) antibodies. 
Cells were acquired on an LSRFortessa cytometer. In some cases, FLS 
fixed, permeabilised and labelled as above, were analysed for 
immunofluorescence microscopy; intracellular staining was performed with 
either 10μg/mL anti-MCP-1 (MA5-17040), 15μg/mL anti-TNF-α (MA5-
23720) or 5μg/mL anti-IL-6 (MA1-22531) antibodies. Secondary labelling 
was performed with anti-mouse IgG-AF488 (F-11021) and anti-rat IgG-
AF488 (A-21208) as appropriate. Primary and secondary cell antibodies 
for immunofluorescence were purchased from ThermoFisher, Waltham, 
USA. 
 
K/BxN serum induced arthritis 
All animal experiments were approved and performed under the guidelines 
of the Ethical Committee for the Use of Animals, Barts and The London 
School of Medicine and in accordance with the UK Home Office regulations 
(Guidance on the Operation of Animals, Scientific Procedures Act, 1986). 
K/BxN arthritis was induced by injecting 8-week-old male C57BL/6 mice 
(Charles River, UK) intraperitoneally with 100μL of K/BxN serum on Day 0 
and Day 2 as described (Patel et al., 2012).  On day 3 mice were 














synovial space with 10μL of either 3×106 MVs (pooled from equal numbers 
of vesicles from 3 human donors) in the left or right ankle, and vehicle 
alone in the other. Which ankle received which treatment was blinded until 
conclusion of the analysis. On day 5, animals were sacrificed, the femurs 
were removed, the ankle synovium was cut and synovia were digested in 
RPMI with 0.5μg/mL collagenase D (11088866001, Sigma-Aldrich) and 
40μg/mL DNAse I (10104159001, Sigma-Aldrich) under agitation at 37oC 
for 30 min before collecting the cell suspension through a 70-μm cell 
strainer. After centrifugation at 300×g for 10 min at 4oC, cells were 
labelled with Zombie Aqua fixable viability dye (423101, Biolegend) to 
exclude dead cells followed by Fc receptor blocking, and staining with 
0.125μg/mL anti-CD11b-BV785 (101243, Biolegend), 2μg/mL anti-F4/80-
BV650 (123149, Biolegend), 2μg/mL anti-CD86-BV421 (105031, 
Biolegend), 5μg/mL anti-MHCII-AF700 (107622, Biolegend), 2μg/mL anti-




Twelve-week old male C57BL/6 mice (Charles River, UK) were injected 
intraperitoneally with 1 mg zymosan (Z4250-1G, Sigma-Aldrich). 
Additional treatments, including 200μg of the antagonist WRW4 (2262, 
Tocris, Bristol, UK) were injected intraperitoneally 48 hours later. After a 














with ice-cold PBS + 2mM EDTA. Supernatants were processed for a TGF-β 
mouse ELISA kit (EMTGFBI, ThermoFisher). 
 
Statistical analysis 
All statistical analyses and graphing were performed in R 3.4.1 or IDEAS 
6.2 for ImageStream plots. Individual biological replicates are shown for 
all data with bars at means; summary statistics quoted in text are 
mean±standard deviation. Analyses used are indicated in each figure 
legend. Linear discriminant analysis (LDA) used scaled and centered 
variables as predictors. 
 
RESULTS 
Generation and characterization of neutrophil MVs  
NTA analysis demonstrated that MVs ranged between 70nm and 400nm in 
diameter, with median diameters of 123±12nm as assessed with 5 
preparations (Figure 1A and 1B). Vesicles in the 100,000xg fraction and 
those remaining in the supernatant had median diameters of 88±18nm 
and 79±9nm, respectively. MV preparations labelled with BODIPY form a 
population of uniformly circular events that separate from noise and can 
be gated to exclude non-singlet events and debris (Figure 1C) by 
ImageStream. Neutrophils from 4 donors stimulated with TNF-α produced 
7.9±1.6x107 vesicles/mL, compared with 2.2±0.5x107 quantified in 
unstimulated cells (Figure 1D). ImageStream analysis of 4 distinct 














phosphatidylserine (i.e. stained with anxA5); 20%±6% MVs were anxA1 
positive; 90%±4% were stained for CD66b while 0.12%±0.04% were 
CD14 positive (representative histograms in Figure 1E), confirming, in 
essence, the lack of contaminating monocyte MVs. 
 
Neutrophil MVs impact on macrophage polarization  
Addition of increasing concentrations of neutrophil MVs to macrophages 
during LPS and IFN-γ-stimulation led to a concentration-dependent 
decrease in HLA-DR/DP/DQ and CD86 expression, returning levels to 
those of unstimulated cells at 3×106 MV/mL (Figure 2A). A concentration-
dependent increase in CD206 expression was also observed. While the 
MVs prevented classical activation of macrophages, they showed no effect 
on IL-4-mediated alternative activation (Supplementary Figure S1). To 
confirm that these actions were attributable to MVs and not exosomes, 
sequential centrifugations of supernatants at 20,000×g and then 
100,000×g yielded enriched preparations of MVs and exosomes, 
respectively. Macrophages undergoing classical activation were 
concomitantly treated with the MV-enriched pellet, exosome-enriched 
pellet, or vesicle-depleted remaining supernatant. While treatment of 
macrophages with the 20,000×g pellet restricted upregulation of HLA-
DR/DP/DQ and CD86 expression during classical activation, and increased 
CD206 expression, treatment with either the vesicle-free supernatant or 















Identification of specific MV determinants 
To establish the potential functional involvement of phosphatidylserine, an 
“eat me” signal which promotes alternative activation of macrophages 
(Scott et al., 2001), exposed on the MVs, assays of classical activation of 
the macrophages were repeated in the presence or absence of anxA5, 
which binds to and buffers phosphatidylserine’s actions (Figure 3). While 
MVs attenuated LPS plus IFN-γ-induced expression of HLA DR/DP/DQ, 
CD86 (Figure 3A), IL-12p70, IL-1β and IL-10 (Figure 3B), and increased 
CD206 expression (Figure 3A), these effects were significantly lost in MVs 
treated with anxA5. Soluble anxA5 was inactive on its own (Figure 3A,3B).  
The only mediator modulated by MV alone was TGF-β (Figure 3B), whose 
production was insensitive to anxA5 addition.  
 
The phagocytosis of apoptotic moieties by macrophages is mediated in 
large part by the receptor-tyrosine kinase MerTK, which is a member of 
the tyro-3/Axl/MerTK family of receptors (Zizzo et al., 2012; Scott et al., 
2001).  To test if MerTK was involved in phosphatidylserine-mediated 
effects, macrophages were classically activated in the presence of MVs or 
vehicle, with or without 10nM UNC-569 (a selective small molecule 
inhibitor of MerTK autophosphorylation) in a 2x2 factorial design (Figure 
4A,4B). Protection against classical upregulation of HLA-DR/DP/DQ, CD86 
and IL-10 by neutrophil MVs was lost in cells treated UNC-569, as was the 
upregulation of CD206 (Figure 4A). There was a similar, though not 














and IL-1β with UNC-569. Conversely, TGF-β secretion was independent of 
UNC-569 treatment (Figure 4B).  
 
As we identified MV anxA1 as one of the determinants for the induction of 
TGF-β secretion from chondrocytes (Headland et al., 2015), macrophages 
were treated with MVs or vehicle, in the presence of anti-anxA1 
neutralizing antibody: quantification of TGF-β concentration in the 
supernatants showed marked TGF-β release above control in all MV-
treated samples in presence of isotype control, but not in samples where 
endogenous anxA1 was neutralised (Figure 4C).  
 
To assess whether the functional engagement of phosphatidylserine or 
anxA1-mediated could be indirect, hence secondary to impacting on the 
uptake of MV by macrophage, CFSE-labelled MV were stained with anxA5 
or anti-anxA1 antibody and added to macrophages, in some cases the 
latter being treated with UNC-569. Figure 4D shows that while blocking 
the interaction between phosphatidylserine and MerTK (with anxA5 or 
UNC-569 respectively) significantly reduces vesicle uptake by 
macrophages, blockade of anxA1 did not produce any alteration. 
Representative images of vesicle-laden macrophages are also shown 
(Figure 4D). 
 
To confirm that anxA1-mediated induction of TGF-β was an extracellular 














2, mice undergoing zymosan-induced peritonitis were injected 
intraperitoneally with 2x107 neutrophil MVs (pooled from 6 donors) with or 
without the selective FPR2 antagonist WRW4. Figure 4E shows that there 
was a significant interaction between vesicle and WRW4 treatments (p = 
0.041), where injection of MVs alone increased peritoneal TGF-β 1.9 fold 
over vehicle alone (p = 0.002), but not in the presence of WRW4 (p = 
0.266; compared with WRW4 alone). 
 
Neutrophil MVs impact on macrophage downstream functions   
Next, we queried if macrophages exposed to neutrophil MVs could interact 
differently with other cells, the choice being primary FLS in view of their 
contiguous presence in the RA synovia. FLS co-cultured with classically-
activated macrophages increased their expression of TNF-α, IL-6, MCP-1, 
CD55 and VCAM-1, compared to those co-cultured with naïve 
macrophages (Figure 5). However, macrophages treated with MVs during 
their activation with LPS plus IFN-γ did not induce upregulation of these 
antigens in the adjacent FLS.  
 
FLS co-cultured with classically-activated macrophages expressed higher 
levels of all antigens measured, compared to those co-cultured with naïve 
macrophages, and FLS co-cultured with alternatively activated 
macrophages expressed higher levels of MCP-1 (Figure 5B). These 
increases in expression were lost in FLS co-cultured with macrophages 














macrophages ‘instructed’ by neutrophil MVs was also visualised by 
immunofluorescence: Figure 5C presents characteristic images for FLS 
immune-reactivity of IL-6, TNF-α and MCP-1 following incubation with 
activated macrophages that had been exposed to vehicle or neutrophil 
MVs. 
 
The effect of RA neutrophil MVs on macrophage polarization 
To test whether MVs generated from RA neutrophils displayed similar 
efficacy to those from healthy controls, RA patient monocyte-derived 
macrophages were classically activated in the presence of 3×106 MV/mL 
from either healthy control or RA neutrophils, or vehicle alone (Figure 6).  
MVs from healthy controls and RA patients shared similar effects across all 
antigens quantified (Figure 6A). LDA showed that macrophages treated 
with either MV preparation separated from vehicle-treated macrophages 
by all antigens, most strongly HLA-DR/DP/DQ, CD86 and TGF-β, along the 
first discriminant factor (which accounted for 88.2% of the variability 
between groups; Figure 6B and factor loadings). Macrophages treated 
with the two MV populations displayed similar expression profiles, 
separating along the second discriminant factor (which accounted for 
11.8% of the variability between groups) by IL-12p70, IL-10, and TGF-β. 
IL-12p70 and IL-10 were more highly expressed in macrophages treated 
with RA MVs, whereas TGF-β (the antigen which varied the greatest 
between them) was more highly expressed by macrophages treated with 














neutrophils could also out-compete the pro-inflammatory effects of total 
MV from RA patient synovial fluid (Supplementary Figures S2 and S3). 
 
The effect of neutrophil MVs in arthritic mice  
To test whether neutrophil MVs could modulate macrophage phenotype in 
vivo, the K/BxN model of arthritis was used. Mice were randomised to 
receive intra-articular injection of 3×106 MV (from healthy controls or RA 
neutrophils) in one ankle, and vehicle in the other. After a further 24hr, 
cells were immune-phenotyped by flow cytometry. Macrophages isolated 
from ankles which received MVs expressed lower MHCII and CD86, and 
higher CD206 compared to their contralateral controls. Intriguingly, these 
differences were more pronounced with MVTNF generated from RA patient 
neutrophils, with joint macrophages from treated ankles exhibiting 
significantly lower MHCII and higher CD206 expression (Figure 6C & D). 
These data supported results from a zymosan-induced peritonitis model of 
acute inflammation, where neutrophil MV reduced macrophage activation 
and increased TGF-β (Supplementary Figures S4 and S5). 
 
DISCUSSION 
In the burgeoning world of vesicle biology, neutrophil MVs are functionally 
different from other MVs as they are endowed with anti-inflammatory and 
pro-resolving properties. Original work of Gasser and Shifferli showed how 
neutrophil MVs could impact on naïve macrophages through release of 














in the presence of macrophage activators, these MVs reduced IL-8 release 
(Gasser & Schifferli, 2004). In our experimental settings, we confirmed 
and extended these observations, noting how neutrophil MVs were 
selective in their ability to modulate LPS + IFN-γ-induced polarization, 
with little effect on the M2 polarization obtained with IL-4. This is in 
agreement with the current literature and, we propose, might be 
considered in the broader pro-resolving properties of neutrophils in the 
context of inflammation resolution (Jones et al., 2016). Not only vesicles, 
but also neutrophil-derived apoptotic bodies can promote important pro-
resolving properties by modifying the behaviour of surrounding cells of 
which the macrophage is a canonical target: macrophage efferocytosis of 
apoptotic neutrophils decreases expression of IL-1 and IL-6 while 
increasing expression of IL-10 and TGF-β (Dalli & Serhan, 2012).  
 
A common mediator in these settings seems to be release of TGF-β. Of 
interest, we have recently reported the central role that this growth factor 
plays in the chondroprotective properties of neutrophil MVs, an effect 
reliant on vesicle-exposed anxA1 (Headland et al., 2015). AnxA1 also 
positively regulates TGF-β signalling in breast cancer cells (de Graauw et 
al., 2010). Modulation of TGF-β release by neutrophil MVs was observed 
even in non-polarised macrophages and could also be significantly 
augmented when cells were activated with LPS+IFN-γ. These data indicate 
at least a partial role for anxA1 present on the MVs as an effector for this 














macrophages, yet there was a genuine engagement of its receptor, 
formyl-peptide receptor type 2, as was indicated from the experiments 
conducted in the presence of its antagonist WRW4. It is intriguing how 
only a proportion of MVs expressed anxA1 on their surface, however we 
have also demonstrated presence of this mediator within the vesicles 
(Dalli et al., 2008). We could also consider how this response may be 
related to a general shift in macrophage phenotype towards an 
alternatively-activated phenotype which produces TGF-β, in line with that 
observed following application of IL-10 or glucocorticoids (Murray et al., 
2014).  
 
At variance from TGF-β and the anxA1/FPR2 axis, most of the markers of 
macrophage polarization were reliant on MV expression of 
phosphatidylserine, since blocking this acidic phospholipid with anxA5 
prevented modulation of HLA-DR, DP & DQ and CD86 on classically-
activated macrophages. We could substantiate these findings by 
establishing an important role for one of the phosphatidylserine receptors, 
the Mer tyrosine kinase or MerTK, as defined through the use of a specific 
inhibitor of its auto-phosphorylation and, hence, receptor activation. 
MerTK is the best characterised member of the tyro-3/Axl/MerTK family of 
receptors, especially in regards to macrophage function: MerTK activation 
in macrophages induces PI3 kinase-mediated phagocytosis and STAT1-
mediated suppression of inflammatory cytokine signalling (Hall et al., 















Taking these reported findings discussed above and the observations 
herein together, we would suggest that phosphatidylserine is both 
important for tethering, uptake, and signalling, but that other components 
are also at work. For example, the reduction in IL-10 production despite 
phosphatidylserine strongly inducing its secretion, is interesting. 
Moreover, while phosphatidylserine is important for internalisation, other 
components of the vesicles may be exerting control over phenotype, such 
as miRNA species.  
 
In our experimental conditions, neutrophil MVs alone did not affect 
macrophage phenotype, suggesting that they inhibit classical activation 
rather than imparting alternative activation. A partial exception occurred 
in the presence of LPS and IFN-γ where the MV actually increased CD206 
expression (an effect seen in neither treatment alone).  
 
An equally important technical observation was made when MV samples 
were compared with exosome-enriched fractions: the data indicate that 
regulation of classical macrophage activation imparted by the MV 
preparations was attributable to the MV-enriched fraction. Equally, 
neutrophil-derived supernatants depleted of all microstructures were 
inactive. Therefore, MV uptake and specific MV effectors, including anxA1, 















During RA, FLS participate in disease progression (Bottini & Firestein, 
2012) by releasing cytokines and growth factors like MCP-1 (Kumkumian 
et al., 1989), VEGF (Palmer et al., 2008), IL-6 (Guerne et al., 1989) and 
GM-CSF (Parsonage et al., 2008), supporting leucocyte recruitment, 
delaying neutrophil apoptosis and propagating pannus hyperplasia. As the 
synovial lining is comprised of both fibroblasts and macrophages, it was 
important to explore whether neutrophil-derived MVs could impact on the 
macrophage-FLS crosstalk. We observed that classically-activated 
macrophages were instructed by the MVs to avoid maximal activation of 
the adjacent FLS, likely an effect downstream of the reduction of classical 
activation in the first place. Nevertheless, the data are suggestive of a 
potential novel mechanism operative in the RA synovia, where neutrophil 
MV-induced regulation of macrophages may have functional consequences 
within the inflamed microenvironment, all signalling towards an anti-
inflammatory outcome. 
 
It was important to ascertain if RA neutrophils could produce MVs able to 
provoke anti-inflammatory effects. Indeed, this was the case, and a 
combination of in vitro and in vivo analyses demonstrated a substantial 
overlap of actions between MVs prepared from neutrophils harvested from 
healthy control or RA patients. The importance of this finding lies in the 
potential of developing innovative therapeutic approaches based on the 















In line with the potential therapeutic exploitation of neutrophil MVs, we 
deemed it important to determine if modulation of macrophage phenotype 
could be attained during ongoing experimental arthritis. Following 
injection of the vesicles into the synovial space in the ankles of arthritic 
mice we could quantify an effective switch of specific macrophage 
markers. These effects were more prominent with neutrophil MV derived 
from RA patients than those generated from healthy controls, for reasons 
we are yet to decipher. Nevertheless, these effects on macrophage 
phenotype confirm the data observed in vitro. Future in vivo experiments 
would help define the therapeutic impact of these vesicles during on-going 
arthritis. 
 
In conclusion, this new study together with current literature that includes 
our own work with chondrocytes and cartilage (Headland et al., 2015), 
presents new mechanistic evidence underpinning the anti-inflammatory 
and anti-arthritic properties of neutrophil MVs, summarised graphically in 
Figure 7. Herein, we shed light on some of the mechanisms responsible 
for the effects of the MV, identifying important determinant roles for 
phosphatidylserine and anxA1. In our view, these data support further 
development of neutrophil vesicles as a ‘polypharma’ therapeutic 
approach for joint disease. 
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Figure 1. Characterization of TNF-α-induced neutrophil MV 
preparations. A, B) Nanosight tracking analyses (NTA) of neutrophils 
MVs. A: two representative density plots of MV, exosome, and 
supernatant after pelleting exosomes at 100,00xg diameters shown with 
cumulative density lines overlaid. Bar plots reports the median diameter of 
each preparations from 5 biological replicates (mean±standard deviation). 
B: representative image of particle light scatter from a sample as analysed 
by NTA. C -E) ImageStream analyses of neutrophil MVs. C: MVs were 
labelled with BODIPY texas red and acquired on an ImageStream. Gating 
strategy shown for gating singlet MV along with representative images of 
singlet and swarm vesicle events. D: Production of MVs from human 
neutrophils (2x107) stimulated with 50ng/mL TNF-α or vehicle, for 20 min 
at 37oC. MVs were quantified by ImageStream. Lines connect samples 
from the same donor; black circles and ranges indicate mean±standard 
deviation. Analysed with Wilcoxon signed rank test. E: Staining of TNF-α-
induced neutrophil MVs to quantify expression of phosphatidylserine 
(PtdSer), annexin A1 (AnxA1), CD66b and CD14. Gating controls for 
CD66b and CD14 were fluorescence minus one, for AnxA1 a secondary 
antibody only control, and for PtdSer annexin A5 in the absence of Ca2+. 
















Figure 2. Neutrophil MVs, but not exosomes, prevent classical 
activation of human macrophages. A) Human monocyte-derived 
macrophages were treated for 24hr with 10ng/mL LPS and 20ng/mL IFN-γ 
alone or with increasing concentrations of neutrophil MVs (pooled from 
equal numbers of vesicles from 3 donors). Macrophages phenotype was 
determined by flow cytometry and compared to naïve macrophages (taken 
as 100%). Data analysed with a linear regression model per antigen, 
where least squares lines and 95% confidence bands are shown. B) 
Macrophages activated as above were treated with 20,000xg pellets 
(microvesicle-enriched), 100,000xg pellets (exosome-enriched), or 
residual supernatant, pooled from 2x107 neutrophils from each of 3 
donors. Macrophages were analysed by flow cytometry and compared to 
naïve macrophages (taken as 100%). Bars indicate group means. Data 
are analysed with Kruskal-Wallis test with Dunn’s post-hoc test per 
antigen, where p values refer to the comparison to the supernatant 
control. 
 
Figure 3. Macrophage polarisation is modulated via 
phosphatidylserine. Human monocyte-derived macrophages were 
treated with combinations of 3×106/mL neutrophil MVs (pooled from 3 
donors, with or without anxA5) and 10ng/mL LPS plus 20ng/mL IFN-γ or 
vehicle for 24hr. Na  ve macrophages were used as negative controls; 
some macrophages were incubated with 50ng/mL IL-4 for 24hr. A) 














Cytokines were quantified in cell supernatant using a Cytometric Bead 
Array. Data are median fluorescence as a percentage of untreated cells for 
surface proteins and absolute concentration for cytokines. Individual 
biological replicates are shown with bars at group means. IL-12p70 could 
not be detected following IL-4 stimulation. Data analysed with separate 
Kruskal-Wallis test with Dunn’s post-hoc tests for each antigen. 
 
Figure 4. Phosphatidylserine-dependent actions of MVs are 
mediated by MerTK. A, B) Human monocyte-derived macrophages were 
treated with 3×106/mL neutrophil EVs (pooled from 3 donors) and 
10ng/mL LPS plus 20ng/mL IFN-γ or vehicle for 24hr. In some cases, 
UNC-569 (10 nM, MerTK inhibitor) or vehicle were also added. Analyses 
for macrophage markers and cytokines were conducted as in Figure 3. C) 
Macrophages were stimulated with 3×106/mL MVs or vehicle, in the 
presence of 10μg/mL anti-anxA1 or isotype control antibodies for 24hr 
before quantification of TGF-β released. D) MVs (pooled from 6 donors) 
were stained with 5μM CFSE, washed, and seeded at 5×106/mL onto 
macrophages. In separate experiments, MVs were either pre-treated with 
50μg/mL anxA5 (or vehicle) or 10μg/mL anti-anxA1 (or isotype control) 
antibody, or macrophages were treated with 10nM UNC-569 (or vehicle). 
Cells were acquired on an ImageStream after different incubation times to 
quantify vesicle internalisation.  Representative images of macrophages 
containing CFSE+ microvesicles are shown. E) TGF-β concentration in the 














intraperitoneally with 2x107 MVs (pooled from 6 human donors) or vehicle 
alone, with or without 200μg WRW4 (FPR2 antagonist), 48hr after injection 
with zymosan. Peritoneal cavities were lavaged 24hr later. Data in A-E 
analysed with separate two-way (three-way for TGF-β) ANOVA with Holm-
  id k post-hoc tests for each antigen. p values in D compare groups at 
each timepoint. Data are median fluorescence as a percentage of 
untreated cells for surface proteins and absolute concentration for 
cytokines. Individual biological replicates are shown. 
 
Figure 5. Effect of neutrophil MVs on macrophage-FLS co-culture. 
A) Experiment scheme. Monocyte-derived macrophages were treated with 
10ng/mL LPS and 20ng/mL IFN-γ, 50ng/mL IL-4 or vehicle for 24hr, in 
the presence of 3x106 MV/mL or vehicle. Macrophages were washed and 
co-cultured with FLS for a further 24hr, after which time FLS were 
immunophenotyped by flow cytometry. The experiment was repeated with 
3 different macrophage donors and the mean across the donors was taken 
for each replicate. B) Antigen expression data for each FLS donor (mean 
expression across co-culture with 3 different macrophage donors) where 
dotted lines indicate median fluorescence of isotype-matched control 
samples. C) Confirmatory immunofluorescence images of IL-6, TNF-α and 
MCP-1 expression after co-culture with macrophages after classical 
activation, in the presence of 3x106 MV/mL or vehicle. Data in B analysed 
















Figure 6. RA patient neutrophils MVs are protective in vitro and in 
vivo. Monocyte-derived macrophages from RA patients were stimulated 
with 10ng/mL LPS and 20ng/mL IFN-γ for 24hr, in the presence of 3x106 
MV/mL prepared and pooled from the cells of 3 healthy donors (HC), 3 RA 
patients (RA) or vehicle. A) Macrophage phenotype and cytokine 
expression after treatment. B) Results of LDA with factor loadings for 
each antigen. C & D) MV impact on inflammatory arthritis. On day 3 of 
serum induced arthritis, mice were injected intra-articularly with 3×106 
MVs from HC or RA donors (each pooled from 3 donors) into 1 ankle, and 
vehicle in the other. After 24hr, synovia were digested, cells extracted and 
macrophages phenotyped by flow cytometry (Gating strategy in C, 
phenotype data in D). Data in A analysed with separate Kruskal-Wallis test 
with Dunn’s post-hoc tests for each antigen. Data in D analysed with 
separate Wilcoxon signed-rank tests for each combination of antigen and 
source of vesicles (HC or RA). 
 
Figure 7. Graphical summary of hypothesis. 
The data presented here support the hypothesis that upon activation with 
tumour necrosis factor (TNF) (and potentially other inflammatory 
mediators), neutrophils rapidly release microvesicles into their local 
environment. Subsets of these vesicles express the pro-resolving protein 
annexin A1 (AnxA1) and/or phosphatidylserine (PtdSer) exposed on their 














response to lipopolysaccharide (LPS) and interferon gamma (IFN-γ), and 
influence their ability to activate other cell types, such as fibroblast-like 
synoviocytes in the rheumatoid synovium. Two mechanisms have been 
identified as responsible for these effects: AnxA1 activating FPR2 and 
inducing the release of transforming growth factor β (TGFβ), and PtdSer 
activating MerTK which blocks classical activation. 
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